得益于核心产品百悦泽(泽布替尼胶囊)和百泽安(替雷利珠单抗)的销售增长,百济神州在2024年取得了显著的业绩增长,亏损较上年同期有所收窄。 28日,百济神州发布了2024年度业绩快报: 营收:2024年度营业总收入达到272.14亿元人民币,同比增长56.2%,其中产品收入为269.94亿元,同比增长74.1%。 净利润:归属于母公司所有者的净利润为-49.78亿元人民币,较上年同期的-...
Source Link得益于核心产品百悦泽(泽布替尼胶囊)和百泽安(替雷利珠单抗)的销售增长,百济神州在2024年取得了显著的业绩增长,亏损较上年同期有所收窄。 28日,百济神州发布了2024年度业绩快报: 营收:2024年度营业总收入达到272.14亿元人民币,同比增长56.2%,其中产品收入为269.94亿元,同比增长74.1%。 净利润:归属于母公司所有者的净利润为-49.78亿元人民币,较上年同期的-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.